Funding for this research was provided by:
Received: 18 October 2017
Accepted: 8 January 2018
First Online: 18 January 2018
Ethics approval and consent to participate
: The study protocol was approved by the regional ethics committee in Uppsala, Sweden (reference number 2014/446).
: Not applicable.
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed (available on request from the corresponding author) and declare: K. Larsson has received honoraria for participation in advisory board meetings and lectures from AstraZeneca, Boehringer Ingelheim, Novartis, Chiesi, Orion, TEVA and Takeda. B. Ställberg has served in advisory board meetings, development of educational presentations and for lectures from AstraZeneca, Novartis, Boehringer Ingelheim, Meda and TEVA. K. Lisspers has received speaking fees from AstraZeneca, Novartis, TEVA and Meda. C. Janson has received honoraria for lectures from AstraZeneca, TEVA and Novartis. G. Telg is a full-time employee of the sponsor, AstraZeneca. G. Johansson and M. Thuresson have no conflicts to report.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.